HRMY vs MRNA
HRMY: Harmony Biosciences is a neuroscience-focused biopharmaceutical company commercializing WAKIX (pitolisant), the first-in-class non-controlled H3 receptor antagonist for narcolepsy, with an expanding pipeline in rare epilepsy and sleep disorders. MRNA: Moderna is a pioneer in mRNA technology, working to transform medicine by developing a broad pipeline of prophylactic vaccines and therapeutic medicines.
Side-by-side fundamentals
| Metric | HRMY | MRNA | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $36.01 | $57.92 | |
| Market cap as of 2026-08-01 | $2.0B | $23.0B | |
| P/E as of 2026-08-01 | 14.01 | n/a | |
| Net margin as of 2026-08-01 | +16.2% | -143.6% | HRMY higher |
| Gross margin as of 2026-08-01 | +76.5% | +35.0% | HRMY higher |
| Operating margin as of 2026-08-01 | +21.1% | -153.3% | HRMY higher |
| ROE as of 2026-08-01 | +17.2% | -36.7% | HRMY higher |
| ROA as of 2026-08-01 | +12.0% | -26.6% | HRMY higher |
| Debt / equity as of 2026-08-01 | 0.17 | 0.09 | MRNA lower |
| Revenue growth (YoY) as of 2026-08-01 | +20.7% | -30.0% | HRMY higher |
| Revenue CAGR (3y) SEC XBRL | +25.6% | -53.4% | HRMY higher |
| Beta as of 2026-08-01 | 0.91 | 0.88 | |
| 1-year return as of 2026-07-27 close | -4.0% | +80.2% | MRNA higher |
Fundamentals: market data, as of 2026-08-01. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.